Is equol production beneficial to health?

Proceedings of the Nutrition Society

Volumn 70, Issue 1, 2011, Pages 10-18

  Magee, Pamela J ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Equol: S equol; Isoflavones; Soya

Indexed keywords

4 HYDROXYNONENAL; ANDROSTANOLONE; DAIDZEIN; DIMETHYLBENZ[A]ANTHRACENE; EQUOL; ESTRADIOL; ESTROGEN RECEPTOR; GENISTEIN; ISOFLAVONE; ISOFLAVONE DERIVATIVE; MENADIONE; PLACEBO; PROGESTERONE; SOYBEAN PROTEIN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANTIOXIDANT ACTIVITY; BONE; BONE DENSITY; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; COHORT ANALYSIS; CONFERENCE PAPER; DIET; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG INHIBITION; DRUG POTENCY; DRUG SAFETY; DRUG TRANSFORMATION; DRUG URINE LEVEL; ESTROGEN ACTIVITY; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; HEALTH; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; INTERVENTION STUDY; INTESTINE FLORA; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MENOPAUSE; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; OBSERVATIONAL STUDY; PHENOTYPE; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SOYBEAN; TUMOR XENOGRAFT;

ANTIOXIDANTS; BONE DISEASES; CARDIOVASCULAR DISEASES; DIHYDROTESTOSTERONE; HOT FLASHES; HUMANS; INTESTINES; ISOFLAVONES; NEOPLASMS; PHENOTYPE; PHYTOESTROGENS; PHYTOTHERAPY; PLANT EXTRACTS; RECEPTORS, ESTROGEN; RISK FACTORS; SOYBEANS;

EID: 79951773667     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665110003940     Document Type: Conference Paper

References (96)

1. Marrian G & Haslewood G (1932) Equol, a new inactive phenol isolated from the ketohydroxyoestrin fraction of mares urine. Biochem J 26, 1227-1232.
2. Axelson M, Kirk DN, Farrant RD et al. (1982) The identification of the weak oestrogen equol [7-hydroxy-3-(4- hydroxyphenyl)chroman] in human urine. Biochem J 201, 353-357. (Pubitemid 12160165)
3. Bennetts HW, Underwood EJ & Shier FL (1946) A specific breeding problem of sheep on subterranean clover pastures in Western Australia. Aust J Agric Res 22, 131-138.
4. Shutt DA (1976) The effects of plant oestrogens on animal reproduction. Endeavour 35, 110-113.
5. Messina M, Nagata C & Wu AH (2006) Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer 55, 1-12. (Pubitemid 44477039)
6. Setchell KDR, Brown NM & Lydeking-Olsen E (2002) The clinical importance of the metabolite equol - a clue to the effectiveness of soy and its isoflavones. J Nutr 132, 3577-3584. (Pubitemid 35435031)
7. Yuan J-P, Wang J-H & Liu X (2007) Metabolism of dietary soy isoflavones to equol by human intestinal microflora - implications for health. Mol Nutr Food Res 51, 765-781. (Pubitemid 47173687)
8. Lampe JW (2009) Is equol the key to the efficacy of soy foods? Am J Clin Nutr 89, 1664S-1667S.
9. Bowey E, Adlercreutz H & Rowland I (2003) Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. Food Chem Toxicol 41, 631-636. (Pubitemid 36349543)
10. Setchell K, Zimmer-Nechemias L, Cai J et al. (1997) Exposure of infants to phyto-oestrogens from soy-based infant formula. Lancet 350, 23-27.
11. Setchell K, Zimmer-Nechemias L, Cai J et al. (1998) Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Am J Clin Nutr 68, 1453S-1461S. (Pubitemid 28550929)
12. Hoey L, Rowland I, Lloyd A et al. (2004) Influence of soyabased infant formula consumption on isoflavone and gut microflora metabolite concentrations in urine and on faecal microflora composition and metabolic activity in infants and children. Br J Nutr 91, 607-616. (Pubitemid 38584785)
13. Brown NM, Belles CA, Lindley SL et al. (2010) The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer. Carcinogenesis 31, 886-893.
14. Setchell KDR, Clerici C, Lephart E et al. (2005) S-equol, a potent ligand for estrogen receptor b, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 81, 1072-1079. (Pubitemid 41724948)
15. Lampe JW, Karr SC, Hutchins AM et al. (1998) Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 217, 335-339.
16. Rowland I, Wiseman H, Sanders TAB et al. (2000) Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer 36, 27-32. (Pubitemid 30317832)
17. Setchell KDR & Cole SJ (2006) Method of defining equolproducer status and its frequency among vegetarians. J Nutr 136, 2188-2193. (Pubitemid 44156823)
18. Tanaka M, Fujimoto K, Chihara Y et al. (2009) Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers. Prostate Cancer Prostatic Dis 12, 247-252.
19. Liu B, Liu A, Uchiyama S et al. (2010) Prevalence of equol producer phenotype and its relations to lifestyle factors and dietary intakes among lifestyle factors and dietary intakes among healthy Chinese adults in Beijing. Wei Sheng Yan Jiu 39, 59-64.
20. Ueno T & Uchiyama S (2001) Identification of the specific intestinal bacteria capable of metabolising soy isoflavone to equol. Ann Nutr Metab 45, 114.
21. Yee S, Burdock GA, Kurata Y et al. (2008) Acute and subchronic toxicity and genotoxicity of SE5-OH, an equol-rich product produced by Lactococcus garvieae. Food Chem Toxicol 46, 2713-2720.
22. Hedlund TE, Maroni PD, Ferucci PG et al. (2005) Long-term dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in Caucasian men. J Nutr 135, 1400-1406. (Pubitemid 40799602)
23. Bolca S, Possemiers S, Herregat A et al. (2007) Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women. J Nutr 137, 2242-2246. (Pubitemid 47529584)
24. McMullen MH, Hamilton-Reeves JM, Bonorden MJ et al. (2006) Consumption of Lactobacillus acidophilus and Bifidobacterium longum does not alter phytoestrogen metabolism and plasma hormones in men: a pilot study. J Altern Complement Med 12, 887-894. (Pubitemid 44770981)
25. Larkin TA, Price WE & Astheimer LB (2007) Increased probiotic yogurt or resistant starch intake does not affect isoflavone bioavailability in subjects consuming a high soy diet. Nutrition 23, 709-718. (Pubitemid 47409961)
26. Larkin TA, Astheimer LB & Price WE (2007) Dietary combination of soy with a probiotic or prebiotic food significantly reduces total and LDL cholesterol in mildly hypercholesterolaemic subjects. Eur J Clin Nutr 63, 238-245.
27. Frankenfeld CL, Atkinson C, Thomas WK et al. (2004) Familial correlations, segregation analysis, and nongenetic correlates of soy isoflavone-metabolizing phenotypes. Exp Biol Med 229, 902-913. (Pubitemid 39539375)
28. Frankenfeld CL, Atkinson C, Thomas WK et al. (2005) High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart. Br J Nutr 94, 873-876. (Pubitemid 43092416)
29. Adlercreutz H, Bowey E, Heinonen SM et al. (2004) Role of the intestine in the production of equol. J Nutr 134, 1234S.
30. Nagel S, vom Saal F & Welshons W (1998) The effective free fraction of estradiol and xenoestrogens in human serum measured by whole cell uptake assays: physiology of delivery modifies estrogenic activity. Proc Soc Exp Biol Med 217, 300-309. (Pubitemid 28130677)
31. Hodgson J, Croft K, Puddey I et al. (1996) Soybean isoflavonoids and their metabolic products inhibit in vitro lipoprotein oxidation in serum. J Nutr Biochem 7, 664-669. (Pubitemid 27019422)
32. Mitchell J, Gardner P, McPhail D et al. (1998) Antioxidant efficacy of phytoestrogens in chemical and biological model systems. Arch Biochem Biophys 360, 142-148. (Pubitemid 29010923)
33. Arora A, Nair M & Strasburg G (1998) Antioxidant activities of isoflavones and their biological metabolites in a liposomal system. Arch Biochem Biophys 356, 133-141. (Pubitemid 28387717)
34. Lund T, Munson D, Haldy M et al. (2004) Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biol Reprod 70, 1188-1195. (Pubitemid 38387732)
35. Martin M, Haourigui M, Pelissero C et al. (1996) Interactions between phytoestrogens and human sex steroid binding protein. Life Sci 58, 429-436. (Pubitemid 26188083)
36. World Cancer Research Fund/American Institute for Cancer Research (2007) Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: AICR.
37. Ferlay J, Shin HR, Bray F et al. (2008) GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer- Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; available at http://globocan.iarc. fr (accessed June 2010).
38. Setchell KDR & Adlercreutz H (1988) Mammalian lignans and phyto-oestrogens. Recent studies on their formation, metabolism and biological role in health and disease. In Role of the Gut Flora in Toxicity and Cancer, pp. 315-345 [I Rowland, editor]. London: Academic Press.
39. Adlercreutz H, Fotsis T, Heikkinen R et al. (1982) Excretion of the lignans enterolactone and enterodiol and of equol in omnivorous and vegetarian women and in women with breast cancer. Lancet 2, 1295-1299.
40. Adlercreutz H, Hockerstedt K, Bannwart C et al. (1988) Association between dietary fiber, urinary excretion of lignans and isoflavonic phytoestrogens, and plasma non-protein bound sex hormones in relation to breast cancer. In Progress in Cancer Research Therarpy, Vol 35: Hormones and Cancer 3, pp. 409-412 [F Bresciani, R King, M Lippman and J-P Raynaud, editors]. New York: Raven Press.
41. Adlercreutz H, Fotsis T, Bannwart C et al. (1986) Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. J Steroid Biochem 25, 791-797. (Pubitemid 17227959)
42. Adlercreutz H, Hockerstedt K, Bannwart C et al. (1987) Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin (SHBG). J Steroid Biochem 27, 1135-1144. (Pubitemid 18020183)
43. Adlercreutz H, Honjo H & Higashi A (1991) Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming traditional Japanese diet. Am J Clin Nutr 54, 1093-1100. (Pubitemid 21917676)
44. Adlercreutz H, Hamalainen E, Gorbach S et al. (1992) Dietary phyto-oestrogens and the menopause in Japan. Lancet 339, 1233.
45. Adlercreutz H, Markkanen H & Watanabe S (1993) Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342, 1209-1210. (Pubitemid 23331713)
46. Adlercreutz H, Goldin B, Gorbach S et al. (1995) Soybean phytoestrogen intake and cancer risk. J Nutr 125, 757S- 770S.
47. Ingram D, Sanders K, Kolybaba M et al. (1997) Case-control study of phyto-oestrogens and breast cancer. Lancet 350, 990-994. (Pubitemid 27421108)
48. Goodman MT, Shvetsov YB, Wilkens LR et al. (2009) Urinary phytoestrogen excretion and postmenopausal breast cancer risk: The Multiethnic Cohort Study. Cancer Prev Res 2, 887-894.
49. Grace PB, Taylor JL, Low Y-L et al. (2004) Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European Prospective Investigation of Cancer and Nutrition - Norfolk. Cancer Epidemiol Biomarkers Prev 13, 698-708. (Pubitemid 38737856)
50. Ward H, Chapelais G, Kuhnle GGC et al. (2008) Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the European Prospective into Cancer-Norfolk cohort study. Breast Cancer Res 10:R32.
51. Messina M (2010) A brief historical overview of the past two decades of soy and isoflavone research. J Nutr 140, 1350S-1354S.
52. Duncan AM, Merz-Demlow BE, Xu X et al. (2000) Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol Biomarkers Prev 9, 581-586. (Pubitemid 30396180)
53. Nettleton JA, Greany KA, Thomas W et al. (2005) The effect of soy consumption on the urinary 2:16-hydroxyestrone ratio in postmenopausal women depends on equol production status but is not influenced by probiotic consumption. J Nutr 135, 603-608. (Pubitemid 40365225)
54. Kabat GC, Chang CJ, Sparano JA et al. (1997) Urinary estrogen metabolites and breast cancer: a case control study. Cancer Epidemiol Biomarkers Prev 6, 505-509. (Pubitemid 27295229)
55. Muti P, Bradlow HL, Micheli A et al. (2000) Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 11, 635-640.
56. Fishman J, Schneider J, Hershcope RJ et al. (1984) Increased estrogen-16 alpha-hydroxylase activity in women with breast and endometrial cancer. J Steroid Biochem 20, 1077-1081. (Pubitemid 14101045)
57. Ursin G, London S, Stanczyk FZ et al. (1999) Urinary 2-hydroxyestrone/ 16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91, 1067-1072. (Pubitemid 29293046)
58. Adlercreutz H, Fotsis T, Hockerstedt K et al. (1989) Diet and urinary estrogen profile in premenopausal omnivorous and vegetarian women and in premenopausal women with breast cancer. J Steroid Biochem 34, 527-530. (Pubitemid 20061839)
59. Frankenfeld CL, McTiernan A, Aiello EJ et al. (2004) Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women. Cancer Epidemiol Biomarkers Prev 13, 1156-1162. (Pubitemid 38917904)
60. Fuhrman BJ, Teter BE, Barba M et al. (2008) Equol status modifies the association of soy intake and mammographic density in a sample of postmenopausal women. Cancer Epidemiol Biomarkers Prev 17, 33-42. (Pubitemid 351196271)
61. Atkinson C, Newton KM, Aiello Bowles EJ et al. (2009) Daidzein-metabolizing phenotypes in relation to mammographic breast density among premenopausal women in the United States. Breast Cancer Res Treat 116, 587-594.
62. Magee PJ & Rowland IR (2004) Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 91, 513-531. (Pubitemid 38584776)
63. Zava DT, Blen M & Duwe G (1997) Estrogenic activity of natural and synthetic estrogens in human breast cancer cells in culture. Environ Health Perspect 105, 637-645. (Pubitemid 27246429)
64. Schmitt E, Dekant W & Stopper H (2001) Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. Toxicol In Vitro 15, 433-439. (Pubitemid 32889670)
65. Magee PJ, Raschke M, Steiner C et al. (2006) Equol: a comparison of the effects of the racemic compound with that of the purified S-enantiomer on the growth, invasion, and DNA integrity of breast and prostate cells in vitro. Nutr Cancer 54, 232-242. (Pubitemid 44316306)
66. Messina M & Wu AH (2009) Perspectives on the soy-breast cancer relation. Am J Clin Nutr 89, 1673S-1679S.
67. Akaza H, Miyanaga N, Takashima N et al. (2004) Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol 34, 86-89. (Pubitemid 43115325)
68. Ozasa K, Nakao M, Watanabe Y et al. (2004) Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 95, 65-71. (Pubitemid 38208409)
69. Hedlund TE, Johannes WU & Miller GJ (2003) Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 54, 68-78. (Pubitemid 36043838)
70. Mitchell JH, Duthie SJ & Collins AR (2000) Effects of phytoestrogens on growth and DNA integrity in human prostate tumor cell lines: PC-3 and LNCaP. Nutr Cancer 38, 223-228. (Pubitemid 32762023)
71. Morton MS, Chan PS, Cheng C et al. (1997) Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong and the United Kingdom. Prostate 32, 122-128. (Pubitemid 27280356)
72. Gardner CD, Oelrich B, Liu JP et al. (2009) Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation. Prostate 69, 719-726.
73. British Heart Foundation Statistics Website (2010) Numbers dying from CVD and CHD, available at http://www. heartstats.org/datapage.asp?id=713 (accessed August 2010).
74. Lichtenstein AH (1998) Soy protein, isoflavones and cardiovascular disease risk. J Nutr 128, 1589-1592. (Pubitemid 28452838)
75. Nagata C (2000) Ecological study of the association between soy product intake and mortality from cancer and heart disease in Japan. Int J Epidemiol 29, 832-836.
76. Food and Drug Administration (1999) Food Labeling: Health Claims, Soy protein and Coronary Heart Disease. Fed Register 64, 57699-57733.
77. Sacks FM, Lichtenstein AH, Van Horn L et al. (2006) Soy protein, isoflavones and cardiovascular health. An American Heart Association science advisory for professionals from the nutrition committee. Circulation 113, 1034-1044. (Pubitemid 43879479)
78. Balk E, Chung M, Chew P et al. (2005) Effects of soy on health outcomes. Evidence report/technology assessment No. 126 (prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No. 290-02- 0022). AHRQ Publication No. 05-E024-2. Rockville, MD: Agency for Healthcare Research and Quality.
79. Zhan S & Ho SC (2005) Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr 81, 397-408. (Pubitemid 43073341)
80. Taku K, Umegaki K, Sato Y et al. (2007) Soy isoflavones lower serum total and LDL cholesterol in humans: a metaanalysis of 11 randomized controlled trials. Am J Clin Nutr 85, 1148-1156. (Pubitemid 46557934)
81. Anderson JW, Johnstone BM & Cook-Newell ME (1995) Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 333, 276-282.
82. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2009). Scientific opinion on the substantiation of a health claim related to soy protein and reduction of blood cholesterol concentrations pursuant to Article 14 of the Regulation (EC) No 1924/2006. EFSA J 8(7): 1688.
83. Meyer BJ, Larkin TA, Owen AJ et al. (2004) Limited lipidlowering effects of regular consumption of whole soybean foods. Ann Nutr Metab 48, 67-78. (Pubitemid 38490245)
84. Hall WL, Vafeiadou K, Hallund J et al. (2006) Soyisoflavone- enriched foods and markers of lipid and glucose metabolism in postmenopausal women: interactions with genotype and equol production. Am J Clin Nutr 83, 592-600. (Pubitemid 44699204)
85. Kreijkamp-Kaspers S, Kok L, Bots ML et al. (2005) Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women. Am J Clin Nutr 81, 189-195. (Pubitemid 43073393)
86. Guo K, Zhang B, Chen C et al. (2010) Daidzein-metabolising phenotypes in relation to serum lipids and uric acid in adults in Guangzhou, China. Br J Nutr 8, 1-7.
87. Ma D-F, Qin L-Q, Wang P-Y et al. (2008) Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials. Eur J Clin Nutr 62, 155-161. (Pubitemid 351234248)
88. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2009). Scientific opinion on the substantiation of health claims related to soy isoflavones and maintenance of bone mineral density (ID 1655) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 7(9):1270.
89. Lydeking-Olsen E, Beck-Jensen J-E, Setchell KDR et al. (2004) Soymilk or progesterone for prevention of bone loss. A 2 year randomized, placebo-controlled trial. Eur J Nutr 43, 246-257. (Pubitemid 39222536)
90. Frankenfeld CL, McTiernan A, Thomas WK et al. (2006) Postmenopausal bone mineral density in relation to soy isoflavone-metabolizing phenotypes. Maturitas 53, 315-324. (Pubitemid 43163067)
91. Kurzer MS (2008). Soy consumption for reduction of menopausal symptoms. Inflammopharmacology 16, 227-229.
92. Uchyama S, Ueno T & Shirota T (2001) The relationship between soy isoflavones and the menopausal symptoms in Japanese perimenopausal women. Ann Nutr Metab 45, 113.
93. Ishiwata N, Melby MK, Mizuno S et al. (2009) New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. Menopause 16, 141-148.
94. Aso T (2010) Equol improves menopausal symptoms in Japanese women. J Nutr 140, 1386S-1389S.
95. Matulka RA, Matsuura I, Uesugi T et al. (2009) Developmental and reproductive effects of SE5-OH: an equolrich soy-based ingredient. J Toxicol ID: 307618, [Epub 15 December 2008].
96. Setchell KDR, Zhao X, Shoaf SE et al. (2009) The pharmacokinetics of S-(-)equol administered as SE5-OH tablets to healthy postmenopausal women. J Nutr 139, 2037-2043.